Friday, October 28, 2016: 12:30 PM-2:00 PM
Room: Poster Hall
Tracks: Pediatric ID, Investigative ID, Adult ID
A Phase I randomized, observer-blind, controlled, dose escalation trial of the safety and tolerability of two intramuscular doses of DPX-RSV(A), a Respiratory Syncytial Virus vaccine containing Respiratory Syncytial Virus (RSV) SH antigen and a novel adjuvant DepoVaxTM, or SH antigen co-administered with Aluminum hydroxide, or placebo to healthy adults ≥50-64 years of age
CME Credits: No CME credit is offered for this session.
See more of: Poster Abstract Session